Nucleic acids for inhibiting expression of LPA in a cell

US11499153B2 · kind B2 · utility

Assignee

• Sapience Therapeutics, Inc. · DE

Inventors

• David Anthony Rider · Berlin, DE
• Lucas Bethge · Potsdam, DE
• Christian Frauendorf · Berlin, DE
• Adrien Weingärtner · Berlin, DE
• Judith Hauptmann · Berlin, DE
• Sibylle Dames · Berlin, DE
• Steffen Schubert · Berlin, DE
• Stephan Tenbaum · Biberach an der Riß, DE

Key dates

• Filing date: Dec 22, 2021
• Grant date: Nov 15, 2022
• Expiry date: Dec 22, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.